Evidence map›Paper›PMID 36194213›Full record

ArticleTransgenic research2022

Points to consider in seeking biosafety approval for research, testing, and environmental release of experimental genetically modified biocontrol products during research and development.

W K Tonui, V Ahuja, C J Beech, J B Connolly, B Dass, D C M Glandorf, S James, J N Muchiri, C F Mugoya, E A Okoree and 2 more

Abstract read
In one paragraph

Article in Transgenic research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. HarnessingFrontiers in microbiology · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

W K TonuiEnvironmental Health Safety Consultancy Ltd., Office 10D, Sifa Towers, Lenana/ Cotton Avenue Junction, Kilimani, Nairobi, Kenya. wtonui@gmail.com.ORCID 0000-0001-5846-7955
V AhujaBiotech Consortium India Limited, New Delhi, India.
C J BeechCambea Consulting Ltd, Reading, UK.ORCID 0000-0001-8348-9566
J B ConnollyImperial College London, London, UK.ORCID 0000-0002-7033-3463
B DassFoundation for the National Institutes of Health, North Bethesda, MD, USA.ORCID 0000-0001-8781-0599
D C M GlandorfGMO Office, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
S JamesFoundation for the National Institutes of Health, North Bethesda, MD, USA.
J N MuchiriNational Biosafety Authority, Nairobi, Kenya.
C F MugoyaTarget Malaria, Kampala, Uganda.
E A OkoreeNational Biosafety Authority, Accra, Ghana.
H QuemadaWestern Michigan University, Kalamazoo, MI, USA.
J RomeisResearch Division Agroecology and Environment, Agroscope, Zurich, Switzerland.ORCID 0000-0003-3652-8360

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel genetically modified biological control products (referred to as "GM biocontrol products") are being considered to address a range of complex problems in public health, conservation, and agriculture, including preventing the transmission of vector-borne parasitic and viral diseases as well as the spread of invasive plant and animal species. These interventions involve release of genetically modified organisms (GMOs) into the environment, sometimes with intentional dissemination of the modification within the local population of the targeted species, which presents new challenges and opportunities for regulatory review and decision-making. Practices developed for GMOs, primarily applied to date for GM crops may need to be adapted to accommodate different types of organisms, such as insects, and different technologies, such as gene drive. Developers of new GM biocontrol products would benefit from an early understanding of safety data and information that are likely to be required within the regulatory dossier for regulatory evaluation and decision making. Here a generalizable tool drawing from existing GM crop dossier requirements, forms, and relevant experience is proposed to assist researchers and developers organize and plan their research and trialing. This tool requires considering specifics of each investigational product, their intended use, and country specific requirements at various phases of potential product development, from laboratory research through contained field testing and experimental release into the environment. This may also be helpful to risk assessors and regulators in supporting their systematic and rigorous evaluation of new biocontrol products.

Indexed as

Containment of BiohazardsCrops, AgriculturalAgricultureAnimalsPlants, Genetically ModifiedResearchRisk AssessmentBiological controlBiosafetyGenetic modificationRegulationRisk assessment

Identifiers

PMID36194213
PMCPMC9531641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.